Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
June 25th, 2018 by Hayley J. Donnella
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer, Published online: 25 June 2018; doi:10.1038/s41589-018-0081-9
Proteomic mapping of dynamic changes in kinase signaling after drug treatment identifies that AURKA inhibition is required for drug sensitivity, representing a new co-targeting opportunity with PI3K, AKT, or mTOR inhibitors in breast cancer.